Eylea wins new approval in Japan; EC to decide on Perrigo buyout by July 29;

@FiercePharma: Egg prices soar, menu items dropped in wake of historic avian flu. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: France's TxCell closes its plant at ANSM urging to avoid contamination. FiercePharmaManufacturing article | Follow @EricPFierce

> Kamil Hamied, who was widely expected to succeed his uncle to lead Indian drugmaker Cipla, has left the company to pursue his own interests. Story

> The European Commission has said it will decide by July 29 whether to allow Mylan ($MYL) to continue its effort to buy Ireland-based Perrigo ($PRGO). Report

> Regeneron ($REGN) says that Bayer, its partner on hot-selling eye drug Eylea, has gained approved of the med in Japan for treating macular edema secondary to branch retinal vein occlusion (BRVO). Release

> Roche ($RHHBY) has opposed French drugmakers who are suggesting the use of its Avastin for off-label use as a cheaper way to treat wet age-related macular degeneration (AMD). Report

Medical Device News

@FierceMedDev: Cinven snatches up Synlab for $1.96B to beef up in diagnostics. FierceDiagnostics news | Follow @FierceMedDev

@VarunSaxena2: Valeant makes offer for Zoetis, sources tell WSJ. FiercePharma story | Follow @VarunSaxena2

@EmilyWFierce: $ILMN just signed a 20-year lease for a new 155,000 square foot scientific research building in England. Release | Follow @EmilyWFierce

> BlackBerry unveils plans for bacteria-free smartphone device. More

> European researchers develop thought-controlled robot. Article

Biotech News

@FierceBiotech: Harvard team makes 'sweating' vehicles for liquid drug delivery. FierceDrugDelivery story | Follow @FierceBiotech

@JohnCFierce: Big story yesterday: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus Hubs win. Report | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> Billionaire Soon-Shiong arranges a $71M crossover round for Conkwest. News

> Seres guts out a $134M IPO to fuel microbiome R&D. Article

> Celladon pulls the plug on R&D after a crushing gene therapy failure. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.